Cancer Rop Co. Ltd. (180400) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cancer Rop Co. Ltd. (180400) has a cash flow conversion efficiency ratio of -0.111x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-10.04 Billion ≈ $-6.81 Million USD) by net assets (₩90.79 Billion ≈ $61.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 180400 net asset quality score to measure how much of total assets are equity-financed.
Cancer Rop Co. Ltd. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Cancer Rop Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cancer Rop Co. Ltd. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Cancer Rop Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cancer Rop Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fiamma Holdings Bhd
KLSE:6939
|
-0.012x |
|
GEVORKYAN as
PR:GEV
|
N/A |
|
Bank Jabar
JK:BJBR
|
-0.231x |
|
Bny Mellon Municipal Income Inc
NYSE MKT:DMF
|
0.000x |
|
Leapfrog Acquisition Corporation Class A Ordinary Shares
NASDAQ:LFAC
|
-0.003x |
|
Limes Schlosskliniken AG
XETRA:LIK
|
0.135x |
|
Emmerson Resources Ltd
AU:ERM
|
-0.329x |
|
GeoVision Inc
TW:3356
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Cancer Rop Co. Ltd. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Cancer Rop Co. Ltd. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Cancer Rop Co. Ltd. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩95.76 Billion ≈ $64.90 Million |
₩-18.85 Billion ≈ $-12.78 Million |
-0.197x | +83.92% |
| 2024-12-31 | ₩16.35 Billion ≈ $11.08 Million |
₩-20.03 Billion ≈ $-13.57 Million |
-1.224x | -192.35% |
| 2023-12-31 | ₩28.80 Billion ≈ $19.51 Million |
₩-12.06 Billion ≈ $-8.17 Million |
-0.419x | -1762.27% |
| 2022-12-31 | ₩34.35 Billion ≈ $23.28 Million |
₩865.55 Million ≈ $586.57K |
0.025x | +117.79% |
| 2018-12-31 | ₩34.91 Billion ≈ $23.65 Million |
₩-4.94 Billion ≈ $-3.35 Million |
-0.142x | -130.41% |
| 2017-12-31 | ₩34.75 Billion ≈ $23.55 Million |
₩-2.14 Billion ≈ $-1.45 Million |
-0.061x | -18.79% |
| 2016-12-31 | ₩29.05 Billion ≈ $19.69 Million |
₩-1.50 Billion ≈ $-1.02 Million |
-0.052x | -32.60% |
| 2015-12-31 | ₩21.56 Billion ≈ $14.61 Million |
₩-841.17 Million ≈ $-570.05K |
-0.039x | -135.75% |
| 2014-12-31 | ₩7.18 Billion ≈ $4.87 Million |
₩783.83 Million ≈ $531.19K |
0.109x | -- |
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more